| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
| Identifiers | |
| CAS Number | |
| Part ofa series on the |
| COVID-19 pandemic |
|---|
 |
|
Medical response |
|
.svg) COVID-19 portal |
S-268019-b is a protein subunitCOVID-19 vaccine candidate developed byShionogi.[1][2]
A study in non-human primates published in 2022 concluded S-268109-b demonstrated efficacy in a SARS-CoV-2 challenge experiment, although neutralizing antibodies against the Omicron variant were reduced.[3]
In a phase 1/2 clinical trial in Japan, the developers concluded reactions to the vaccine were mild, and neutralizing antibodies were similar to those in people who had recovered from Covid-19.[4] A phase 3 trial planned for 54,915 participants began in December 2021 in Vietnam.[5]
Preliminary results of a phase 2/3 trial using S-268019-b as a booster dose after two doses of theBNT162b2 vaccine by Pfizer concluded the vaccine was non-inferior to a booster dose of BNT162b2.[6]
.png) | This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it. |
 | This article aboutvaccines orvaccination is astub. You can help Wikipedia byexpanding it. |
